Top

Tag: atrial fibrillation


FDA, Regulations

Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program

May 16, 2023

Via: World Pharma News

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news […]